Exact Sciences

503 articles about Exact Sciences

• Exact Sciences To Acquire Thrive Earlier Detection, Becoming A Leader In Blood-Based, Multi-Cancer Screening

  10/27/2020

  Brings Together Cancer Screening R&D Pioneers to Transform the Future of Cancer Diagnostics and Impact Lives

• Exact Sciences Announces Third Quarter 2020 Results

  10/27/2020

  Exact Sciences Corp. announced that the company generated revenue of $408.4 million for the third quarter ended September 30, 2020, compared to $218.8 million for the same period of 2019.

• 

  Exact Sciences to Acquire Thrive in Deal Valued at $2.15 Billion

  10/27/2020

  The deal, which is worth up to $2.15 billion, is expected to close in the first quarter of 2021 and is subject to regulatory approval.

• Exact Sciences Selects Veeva Vault Clinical Suite to Help Accelerate Innovation

  10/14/2020

  Veeva Systems announced that Exact Sciences, a leading provider of cancer screening and diagnostic tests, selected Veeva Vault Clinical Suite to design and run its clinical studies.

• Exact Sciences Introduces the Oncotype MAP™ Pan-Cancer Tissue Test to Help Guide Treatment for Patients with Advanced Cancer

  10/12/2020

  Exact Sciences Corp. (NASDAQ: EXAS) today announced the introduction of the Oncotype MAP™ Pan-Cancer Tissue test for patients with advanced, metastatic, refractory, or  recurrent cancer. The Oncotype

• Exact Sciences schedules third quarter 2020 earnings call

  10/9/2020

  Exact Sciences Corp. announced that the company plans to release its third quarter 2020 financial results after the close of the U.S. financial markets on October 29, 2020.

• Exact Sciences and Pfizer Extend and Amend Cologuard® Promotion Agreement

  10/7/2020

  Exact Sciences Corp. and Pfizer Inc. announced an extension and amendment of their agreement to promote Cologuard, the first and only FDA-approved non-invasive stool DNA screening test for colorectal cancer.

• Exact Sciences to participate in Cowen Liquid Biopsy Summit

  9/17/2020

  Exact Sciences Corp. announced that company management will participate in the following event and invited investors to participate by webcast.

• Exact Sciences to participate in September investor conference - Sep 01, 2020

  9/1/2020

  Exact Sciences Corp. announced that company management will participate in the following conference and invited investors to participate by webcast.

• Exact Sciences to participate in August 2020 investor conference

  8/3/2020

  Exact Sciences Corp. announced that company management will participate in the following conference and invited investors to participate by webcast.

• Exact Sciences schedules annual meeting, second quarter 2020 earnings call

  7/8/2020

  Exact Sciences Corp. announced that the company has scheduled its virtual annual stockholders meeting and second quarter 2020 earnings call.

• Oncotype DX Genomic Prostate Score® Result Shows for the First Time the Value of the Test to Guide Treatment Plans for Unfavorable Intermediate-Risk Prostate Cancer Patients

  6/16/2020

  Findings, published in Urology, suggest that GPS™ results can help guide the intensity of clinical management in this higher-risk patient population

• Exact Sciences Showcases Continued Progress in Cancer Diagnostics at ASCO 2020

  5/29/2020

  - New data and society guidelines support value of Oncotype DX Breast Recurrence Score® test in guiding neoadjuvant treatment decisions for newly diagnosed patients - Mayo Clinic collaboration yielding new data and insights on some of the deadliest cancers

• Exact Sciences to participate in June 2020 investor conferences

  5/26/2020

  Exact Sciences Corp. announced that company management will participate in the following conferences and invited investors to participate by webcast.

• New Oncotype DX® Real-world Evidence Shows for the First Time the Practice-changing Impact of TAILORx Results

  5/14/2020

  Data obtained in real-life setting from more than 800 patients with node-negative or node-positive early-stage breast cancer highlight the test's impact on clinical practice with chemotherapy-sparing effect

• Exact Sciences Announces First Quarter 2020 Results

  5/6/2020

  Exact Sciences Corp. announced that the company generated revenue of $347.8 million for the first quarter ended Mar. 31, 2020, compared to $162.0 million for the same period of 2019.

• Exact Sciences to participate in May 2020 investor conference

  5/4/2020

  Exact Sciences Corp. announced that company management will participate in the following investor conference and invited investors to participate by webcast..

• Exact Sciences Highlights The Opportunity To Seek Screening With Cologuard® Through Telehealth

  4/2/2020

  Exact Sciences Corp. announced it would be devoting significant patient education resources toward the ability to request Cologuard® online through a telehealth provider.

• Exact Sciences Takes Action during COVID-19 Pandemic

  3/19/2020

  Exact Sciences Corp. provided an update on the actions it is taking to support patients, employees, and public health initiatives in response to the coronavirus pandemic.

• Exact Sciences Extends Leadership In Advanced Cancer Diagnostics With Acquisitions Of Paradigm And Viomics

  3/3/2020

  Exact Sciences Corp. announced the completion of its acquisitions of Paradigm Diagnostics, Inc. and Viomics, Inc., two privately held companies based in Phoenix.